When bad news drops, investors have a tendency to sell first and ask questions later. Let's take a closer look at why Viking ...

The FDA has approved semaglutide for treating MASH, a significant advancement in liver disease management. Semaglutide, ...

The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated ...

MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.

The approval was based on Part 1 (72 week data) of the randomized, double-blind, placebo-controlled phase 3 ESSENCE trial.

The European Commission (EC) has granted conditional marketing authorization for Madrigal Pharmaceuticals' Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic metabolic ...

Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has been approved in Europe for the treatment of metabolic ...

This is one huge reason to believe in the future of Novo Nordisk (NYSE: NVO), the Danish company behind the immensely popular Wegovy obesity treatment. Last week the company earned a new feather in ...

The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...

The condition starts off as non-alcoholic, or as it is now known metabolic-associated, fatty liver disease. This fat build-up, over time, leads to inflammation and scarring of the liver, reducing the ...

Health Canada approved Ozempic for type 2 diabetes patients with chronic kidney disease after positive FLOW trial results.

Wegovy is now positioned as the first and only GLP-1 treatment.